Schallenkamp, John M, MD - Sheridan ...

Dr. John M. Schallenkamp

Claim this profile

Billings Clinic Cancer Center

Expert in Skin Cancer
Expert in Lung Cancer
206 reported clinical trials
267 drugs studied

Area of expertise

1Skin Cancer
Global Leader
John M. Schallenkamp has run 86 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
John M. Schallenkamp has run 32 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Billings Clinic Cancer Center
Image of trial facility.
Saint Alphonsus Cancer Care Center-Boise

Clinical Trials John M. Schallenkamp is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria

More about John M. Schallenkamp

Clinical Trial Related6 years of experience running clinical trials · Led 206 trials as a Principal Investigator · 101 Active Clinical Trials
Treatments John M. Schallenkamp has experience with
  • Nivolumab
  • Carboplatin
  • Pembrolizumab
  • Cisplatin
  • Paclitaxel
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John M. Schallenkamp specialize in?
John M. Schallenkamp focuses on Skin Cancer and Lung Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is John M. Schallenkamp currently recruiting for clinical trials?
Yes, John M. Schallenkamp is currently recruiting for 99 clinical trials in Billings Montana. If you're interested in participating, you should apply.
Are there any treatments that John M. Schallenkamp has studied deeply?
Yes, John M. Schallenkamp has studied treatments such as Nivolumab, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with John M. Schallenkamp?
Apply for one of the trials that John M. Schallenkamp is conducting.
What is the office address of John M. Schallenkamp?
The office of John M. Schallenkamp is located at: Billings Clinic Cancer Center, Billings, Montana 59101 United States. This is the address for their practice at the Billings Clinic Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security